An observational, prospective cohort study to evaluate the long term safety and effectiveness of intravenous CT-P13 (biosimilar of infliximab) in patients with Crohn's Disease or Ulcerative Colitis

被引：1
|
作者：
Cheon, J. H. [1 ,2 ]
Kang, H. W. [3 ]
Lee, S. J. [4 ]
Kim, S. H. [5 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Inst Gastroenterol, Seoul, South Korea
[3] SMG SNU Boramae Med Ctr, Div Gastroenterol & Hepatol, Dept Internal Med, Seoul, South Korea
[4] CELLTRION Inc, Div Clin Dev, Incheon, South Korea
[5] CELLTRION Inc, Clin Planning, Incheon, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.482
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P358
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [31] EFFECTIVENESS AND SAFETY IN CROHN'S DISEASE PATIENTS WHO WERE TREATED WITH CT-P13
    Choe, Yon Ho
    Lee, Suck-Ho
    Park, Dongil
    Lee, Ji Hyun
    Kim, Hyo-Jong
    Kim, Young Ho
    Choi, Chang Hwan
    Eun, Chang Soo
    Lee, Sang Joon
    Lee, SunHee
    GASTROENTEROLOGY, 2017, 152 (05) : S406 - S406
  • [32] BIOSIMILAR INFLIXIMAB (CT-P13) IS NOT INFERIOR TO ORIGINATOR INFLIXIMAB: EXPLORATIVE IBD SUBGROUP-ANALYSES IN CROHN'S DISEASE AND ULCERATIVE COLITIS FROM THE NOR-SWITCH TRIAL
    Joergensen, Kristin K.
    Olsen, Inge C.
    Goll, Guro L.
    Lorentzen, Merete
    Bolstad, Nils
    Berset, Ingrid P.
    Haavardsholm, Espen A.
    Lundin, Knut E.
    Mork, Cato
    Kvien, Tore K.
    Jahnsen, Jorgen
    GASTROENTEROLOGY, 2017, 152 (05) : S65 - S66
  • [33] Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial
    Jorgensen, K. K.
    Olsen, I. C.
    Goll, G. L.
    Lorentzen, M.
    Bolstad, N.
    Berset, I. P.
    Haavardsholm, E. A.
    Lundin, K. E.
    Mork, C.
    Kvien, T. K.
    Jahnsen, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S62 - S63
  • [34] Comparison of the pharmacokinetics of CT-P13 between Crohn's Disease and Ulcerative Colitis in biologic-naive patients; a prospective multi-center observational study of the KASID
    Kim, E. S.
    Park, D. I.
    Kim, H. J.
    Lee, Y. J.
    Koo, J. S.
    Kim, E. S.
    Yoon, H.
    Lee, J. H.
    Kim, J. W.
    Shin, S. J.
    Kim, H. W.
    Kim, H. S.
    Park, Y. S.
    Kim, Y. S.
    Kim, T. O.
    Lee, J.
    Choi, C. H.
    Han, D. S.
    Chun, J.
    Kim, H. S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S101 - S102
  • [35] Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
    Yoo, Dae Hyun
    Prodanovic, Nenad
    Jaworski, Janusz
    Miranda, Pedro
    Ramiterre, Edgar
    Lanzon, Allan
    Baranauskaite, Asta
    Wiland, Piotr
    Abud-Mendoza, Carlos
    Oparanov, Boycho
    Smiyan, Svitlana
    Kim, HoUng
    Lee, Sang Joon
    Kim, SuYeon
    Park, Won
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) : 355 - 363
  • [36] Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
    F. Argüelles-Arias
    M. F. Guerra Veloz
    R. Perea Amarillo
    A. Vilches-Arenas
    L. Castro Laria
    B. Maldonado Pérez
    D. Chaaro
    A. Benítez Roldán
    V. Merino
    G. Ramírez
    A. Caunedo Álvarez
    M. Romero Gómez
    Digestive Diseases and Sciences, 2017, 62 : 2203 - 2203
  • [37] Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn's disease and ulcerative colitis
    Gheorghe, C.
    Svoboda, P.
    Dimitriu, A.
    Mateescu, B.
    Kotzev, I.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S316 - S317
  • [38] Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13
    Parigi, Tommaso Lorenzo
    D'Amico, Ferdinando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 37 - 46
  • [39] Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
    Gecse, Krisztina B.
    Lovasz, Barbara D.
    Farkas, Klaudia
    Banai, Janos
    Bene, Laszlo
    Gasztonyi, Beata
    Golovics, Petra Anna
    Kristof, Tuende
    Lakatos, Laszlo
    Csontos, Agnes Anna
    Juhasz, Mark
    Nagy, Ferenc
    Palatka, Karoly
    Papp, Maria
    Patai, Arpad
    Lakner, Lilla
    Salamon, Agnes
    Szamosi, Tamas
    Szepes, Zoltan
    Toth, Gabor T.
    Vincze, Aron
    Szalay, Balazs
    Molnar, Tamas
    Lakatosa, Peter L.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (02): : 133 - 140
  • [40] A French nationwide prospective study on patients with Crohn's disease and ulcerative colitis treated with Infliximab-biosimilar CT-P13 in a real-life setting: two-year follow-up of the ReFLECT study
    Bouhnik, Y.
    Nancey, S.
    Assing, M.
    Mammar, N.
    Laharie, D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S320 - S321
12345